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Abstract: Kynurenic acid (KYNA), a metabolite of tryptophan, as an excitatory amino acid receptor
antagonist is an effective neuroprotective agent in case of excitotoxicity, which is the hallmark of brain
ischemia and several neurodegenerative processes. Therefore, kynurenine pathway, KYNA itself,
and its derivatives came into the focus of research. During the past fifteen years, our research group
has developed several neuroactive KYNA derivatives, some of which proved to be neuroprotective
in preclinical studies. In this study, the synthesis of these KYNA derivatives and their evaluation
with divergent molecular characteristics are presented together with their most typical effects on the
monosynaptic transmission in CA1 region of the hippocampus of the rat. Their effects on the basic
neuronal activity (on the field excitatory postsynaptic potentials: fEPSP) were studied in in vitro
hippocampal slices in 1 and 200 µM concentrations. KYNA and its derivative 4 in both 1 and 200 µM
concentrations proved to be inhibitory, while derivative 8 only in 200 µM decreased the amplitudes of
fEPSPs. Derivative 5 facilitated the fEPSPs in 200 µM concentration. This is the first comparative study
which evaluates the structural and functional differences of formerly and newly developed KYNA
analogs. Considerations on possible relations between molecular structures and their physiological
effects are presented.
Keywords: kynurenic acid; Mannich reaction; neuroprotection; excitatory amino acid receptors
1. Introduction
Glutamate is the main excitatory neurotransmitter in the central nervous system (CNS) that acts
both on ionotropic and metabotropic receptors. The excessive glutamate level results in excitotoxicity
which is the hallmark of several neurodegenerative processes. Excitotoxicity may result from acute
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events like stroke or traumatic brain injury [1–3]. On the other hand, it plays a role in several
neurological diseases [4].
In case of high glutamate level, the receptors of excitatory amino acids
(EAARs) such as N-methyl-d-aspartate ionotropic glutamate receptor (NMDAR),
alfa-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPAR), and kainate receptors
are overactivated, leading to neuronal damage. The overactivation of these receptors can lead
to dysregulation of Ca2+ homeostasis, triggering the production of free radicals, oxidative stress,
mitochondrial dysfunctions, and finally cell death [5]. The NMDAR is a ligand-gated ion channel
that plays an outstanding role in these pathological processes; therefore, it is a potential therapeutic
target [6].
Several preclinical studies showed that the attenuation of excitotoxicity may be achieved
by blockage of EAARs such as NMDAR [7–10]. Although it is clear that NMDAR antagonists,
such as MK-801, prevents excitotoxicity [11,12], their clinical use is very limited, as a complete
NMDAR blockade resulting from their usage can cause serious side effects such as nausea, vomiting,
and memory impairment [13]. Additionally, NMDAR blockers may produce psychosis and symptoms
of schizophrenia in humans, while in laboratory animals it can induce ataxia and stereotypy [14–16].
However, N-methyl-d-aspartate receptor (NR2B) subunit-specific antagonists glycine (Gly) and
polyamine site agents and ion channel blockers with low affinity got into the focus of research,
as they have attenuated the side effects [17]. This was the reason why kynurenic acid (KYNA),
an intermediate of the tryptophan metabolism [18,19], also came into the interest of researchers.
KYNA is the only known endogenous NMDAR blocker (beside Mg2+) that also has broad-spectrum
targets: it inhibits NMDARs at Gly-binding site [20] and it can noncompetitively inhibit α7-nicotinic
acetylcholine receptors [21], and through this, it can moderate Glu release presynaptically [22]. KYNA
has been proposed as the endogenous agonist of G protein-coupled receptor 35 (GPR35), a Gi-protein
receptor [23], and a nuclear receptor, called aryl hydrocarbon receptor (AHR) [24]. In addition to the
direct effects of KYNA on glutamatergic neurotransmission, an indirect inverse regulation between
striatal KYNA and dopamine (DA) levels has also been raised [25].
Reviewing the wide spectrum of effects of KYNA, it can be concluded that KYNA proved to be a
neuroprotective substance in most preclinical studies [26–28]. This has stimulated the intense study
of KYNA itself and of its derivatives, design, and development of new KYNA analogs, prodrugs,
and derivatives [18,29,30].
More than fifteen years ago, our research group also started to develop
new KYNA derivatives. One of our molecules (4), a KYNA amide derivative
N-(N’,N’-dimethylaminoethyl)-4-hydroxy-4-quinoline-2-carboxamide hydrochloride), showed
electrophysiological properties similar to KYNA in in vitro studies [31], proved to be protective
in a transgenic animal model of Huntington’s disease [32] and also in many other preclinical
studies [33–36].
In this article, the synthesis of neuroactive KYNA derivatives and their basic electrophysiological
effects studied in in vitro are presented. The tests were carried out in normal artificial cerebrospinal
fluid (ACSF).
2. Results
2.1. Design and Development of KYNA Derivatives
The synthesis of the precursor ethyl 4-hydroxyquinoline-2-carboxylate (3) has already been
published [37]. During that process, aniline was reacted with diethyl acetylenedicarboxylate, forming
the intermediate enamine. In the second ring-closing reaction in diphenyl ether at 250 ◦C led to the
formation of the ethyl ester in an overall yield of 58%. In our case, the following optimizations were
applied: (i) After the formation of the enamine 2, column chromatography was used to purify the
intermediate; (ii) Diphenyl-ether was replaced by 1,2-dichlorobenzene that has lower boiling point
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(190 ◦C) allowing an easier work-up procedure. These latter conditions led to the formation of 3 in an
overall yield of 67% (Scheme 1).
Scheme 1. Syntheses of KYNA ethyl ester.
Compounds 4, 5 were synthesized by direct amidation of the ethyl ester of KYNA (3)
with N1,N1-dimethylethane-1,2-diamine (to achieve 4) or with N1,N1-dimethylpropane-1,3-diamine
(to achieve 5) (Scheme 2).
Scheme 2. Syntheses of KYNA amide derivatives.
As previous studies indicated, the addition of a proton acceptable nitrogen is preferable for better
biological activity [38]. This can be achieved either through amidation using amines containing tertiary
nitrogen (Scheme 2), or via modified Mannich reaction (mMR) by using secondary amine derivatives.
It has been suspected that the presence of multiple cationic centers together will contribute to the
biological effect with greater magnitude. Thus, the syntheses of 7 and 8 containing two such functional
groups were planned in a step by step synthetic pathway (Scheme 3). First, the synthesis of 6 was
carried out. During the aminoalkylation of 3, morpholine as a representative secondary cyclic amine
with formaldehyde was used to form the iminium salt that would attack the C-3 position on the
KYNA skeleton. Afterward, the amidations of 6 were achieved in dimethylformamide through the
activation of the free carboxylic group with N,N′-diisopropylcarbodiimide (DIC). During the reactions,
1-hydroxybenzotriazole hydrate (HOBt) was also used to achieve an active-ester intermediate and
further improve the yield (Scheme 3).
Scheme 3. Syntheses of aminoalkylated KYNA amide derivatives.
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2.2. Electrophysiology
Schaffer collateral-stimulation results in field excitatory postsynaptic potentials (fEPSPs) in the
pyramidal layer of region CA1 of the hippocampus with 0.5–0.8 mV amplitudes (Figure 1A, inset).
Administration of KYNA or the presented KYNA derivatives in 200 µM concentration resulted in
either decrease or increase in the amplitudes of the fEPSPs. KYNA derivatives (except 4 and 5) applied
in 1 µM concentration induced less unequivocal and significant changes.
Figure 1. Effect of KYNA and 4 (one of its derivatives) on the field excitatory evoked potentials (fEPSPs)
recorded in CA1 region of hippocampus. A: KYNA administration (in 200 µM concentration) for 30 min
resulted in decrease of the fEPSPs’ amplitudes reversibly. During wash-out, the amplitudes not only
recovered but also were facilitated in the recorded period (arrow) *: samples for the baseline were
taken during the last 5 min of control period. #: samples for calculation of the effect were taken during
the last 5 min of wash-in period. Inset: an original fEPSP. Amplitudes were measured from ‘a’ to ‘b’.
Calibration: 20 ms and 0.5 mV. B: dose-dependent responses to KYNA and 4 in concentrations 1 µM,
16 µM, and 200 µM, respectively. In case of KYNA, n = 7 at 1 µM and 16 µM and n = 10 at 200 µM.
In case of 4 n = 10 at 1 µM and 16 µM and n = 8 at 200 µM.
Following the control period, an immediate decrease in fEPSP amplitudes could be detected at
the wash-in period of KYNA (200 µM) (Figure 1A). The maximal reduction was 25%–30% compared
to controls, which lasted until the end of wash-in (Figure 1A). During wash-out period, amplitudes
started to rise immediately, and after 20–25 min, they became stable, showing a 6%–8% increase
compared to the controls (arrow in Figure 1A). KYNA and 4 (a KYNA amide), both in 1 µM and 200 µM
concentrations, resulted in significant decrease in the amplitude (Figure 2 KYNA and compound 4).
To show the effect of 4 in comparison with KYNA in more detailed, dose–effect relations are presented
(Figure 1B). The effect of 5 is fundamentally different. Its administration at 200 µM concentration
resulted in 15%–25% facilitation of fEPSPs amplitudes, while in 1 µM concentration its effect was
slightly inhibitory (Figure 2, compound 5).
Though the structures of 7 and 8 are similar to each other, their effects are different. Administration
of 7 in 200 µM concentration induced a slight increase in the amplitudes of fEPSPs during the wash-in
period, while in 1 µM, it had a weak inhibitory effect, but none of them proved to be significant
(Figure 2, compound 7). In case of 8, the results acquired during the administration were not stable.
In most cases it (in 200 µM) resulted in a serious decrease in amplitudes (to 60% of controls, e.g.,
Figure 2, compound 8), and in few cases, the inhibitory effect of 8 was smaller. In 1 µM concentration,
it had hardly any effect.
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Figure 2. Structure and molecular weight of KYNA and of its derivatives (4, 5, 7, 8), respectively,
together with their effects on the field excitatory postsynaptic potentials (fEPSPs) recorded in CA1
region of hippocampus. Control (c) was observed during the last 5 min of resting period, before
administration of a compound (* in Figure 1A). Effect on the amplitudes of fEPSPs was observed during
the last 5 min of wash-in periods, respectively (# in Figure 1A). Each slice was subjected to only one
measurement. Changes in fEPSP amplitudes (mean ± SEM) due to application of KYNA or of its
analogs are shown in the bar graphs. The numbers of measurements (N) are indicated in the columns;
n.s. = p > 0.05; **p < 0.01; ***p < 0.001).
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3. Discussion
A mass of early results from other laboratories [39–41] and our own previous studies demonstrated
that neuroprotection can be achieved not only with KYNA but also by administration of either
kynurenine (KYN, the prodrug of KYNA) or KYNA derivatives [10,26,42–45]. During the past
one and half decade, we have made great efforts to develop new KYNA derivatives which are
neuroactive (and hopefully protective in such pathological states as ischemia or in the models of
different neurological diseases) [28,30,46].
In this study, we focused on four neuroactive KYNA derivatives; keeping in mind the structure of
molecules and the effects of substances on the neuronal transmission in a relatively simple monosynaptic
preparation (Schaffer collateral/commissural pathway - pyramidal cells). The induced fEPSPs well
demonstrate the neural signaling, in which mainly NMDA and AMPA receptors are involved [47,48].
The electrophysiological studies were carried out both in lower and higher concentrations (1 and
200 µM, respectively). While KYNA and 4 decreased the amplitudes effectively in both concentrations,
the effect of derivatives 5, 7, and 8 in 1 µM concentration was insignificant. In this study, we focused on
the 200 µM concentration because in another series of experiments, aiming to study the phenomenon
of neuroprotection, that concentration was used. KYNA administration resulted in reduction in
amplitudes of fEPSPs, which can be well explained by its binding to the strychnine-insensitive glycine
binding site of the NMDA receptor [20]. After KYNA application, during the wash-out period,
the fEPSPs not only recovered but they were also augmented. Looking for explanation, one can think of
the results of Prescott et al., who found that KYNA has a dual action on AMPA receptors [49]. Similarly,
we found that KYNA has a Janus-faced effect on fEPSPs; in micromolar range it has inhibitory, while in
nanomolar range it has facilitatory effect [50]. This might be based on that during the wash-out period
the KYNA concentration gradually decreased to nanomolar range.
The phenomenon was true for 4 as well; significant decrease in amplitudes of fEPSPs was
observed during its administration in all studied concentrations. To demonstrate the similar inhibitory
properties of KYNA and 4, their dose-dependent responses were presented (Figure 1B). Similar result
was published by Marosi et al. [31]. 4 was our firstly synthesized KYNA amide, effective as an
inhibitor of fEPSPs in in vitro studies, and it proved to be outstandingly effective in earlier studies of
neuroprotection [31,32,43,51]. It was effective also in systemic administration, which suggests that
4 might penetrate the blood-brain barrier (BBB) much more effectively than KYNA [30]. It can be
explained by the molecular structure of 4 as it has a side chain containing cationic center that may
help the penetration through the BBB and through the creation of hydrochloride salt it can grant
water solubility.
Contrary to the small structural difference (5 differs from 4 only in a -CH2- in the side chain),
the effect of 5 is fundamentally different; its administration (in 200 µM) did not induce inhibition of
fEPSPs but facilitated the amplitudes (Figure 2, compound 5). Similar results were also found in the
early tests of these molecules made on anesthetized animals [30].
The difference between the molecular structures of 7, 8 and 4, 5 is that the latter compounds are
unsubstituted at position 3, while 7 and 8 are aminoalkylated at C-3 of the KYNA skeleton. Though
7 and 8 have similar structure (the only difference between the two molecules is the cationic center
of the amide side chain), their effects (in 200 µM) were fundamentally different; 7 resulted in a slight
but insignificant facilitation while 8 in most cases induced a marked inhibition of fEPSP amplitudes
(Figure 2, compounds 7 and 8).
Although it is hard to discuss comprehensive correlations between structure and biological effects,
we could determine certain structural changes leading to different biological activity. Compound 4,
as previously investigated, shows similar effect as KYNA; however, the insertion of an additional
-CH2-group in the amide sidechain (compound 5) resulted in an antagonist effect. Similar results were
observed during the evaluation of compound 7 that bears the amide sidechain of 4 and an additional
aminoalkyl group at C-3. These results mean that the insertion of an additional cationic center at
position 3 has a characteristic influence on the electrophysiological effects.
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The explanation of the phenomenon is not clear. Probably, it cannot be elucidated simply with
the binding to the synaptic AMPA- and/or NMDA receptors. It is known that beside the synaptic
glutamatergic receptors, perisynaptic and extrasynaptic receptors exist, which are distinct from each
other [52–55]. Basically, according to the subunit composition, in adults, GluN2A subunits of NMDA
receptors are predominantly synaptic, GluN2B-containing receptors are mostly extrasynaptic, though
it is not true in all cases, for example, GluN2B subunits are also located in synapses in several
brain regions [56]. Activation of these extrasynaptic receptors leads to changes in excitability of
neurons and take part in several pathological processes like excitotoxicity, neurodegeneration, or
neuroinflammation [57]. It might be that the amplitudes’ changes involve different mechanisms.
Our most effective molecules are KYNA amides, which are known to be capable of the selective
inhibition of the NR2B subunit-containing NMDA receptors [58]. However, the effects of different
neuroactive KYNA derivatives have never been compared keeping in mind their structure. This is the
first comparative study which evaluates the structural and functional differences of formerly and newly
developed KYNA analogs. Unfortunately, at this moment, we do not know more details about the
binding of these molecules to the different synaptic and extrasynaptic glutamatergic receptors, but the
results of these preclinical studies are promising, as these KYNA derivatives might be promising
candidates for clinical trials.
4. Materials and Methods
4.1. Drugs
KYNA was from Sigma-Aldrich (Steinheim, Germany). Compounds (5, 7, 8) in these studies were
used at final concentration of 1 and 200 µM, respectively, while KYNA and 4 in concentrations of 1, 16,
and 200 µM, dissolved in normal ACSF. The pH of the solutions was continuously monitored and kept
at 7.4.
4.2. Synthesis
The 1H and 13C spectra were recorded in DMSO or D2O solutions in 5 mm tubes, at room
temperature, with a Bruker spectrometer (Karlsruhe, Germany) at 500 (1H) and 125 (13C) MHz, with
the deuterium signal of the solvent as the lock and TMS as internal standard.
Melting points were determined on a Hinotek X-4 melting point apparatus (Ningbo, China).
Elemental analyses were performed with a Perkin-Elmer 2400 CHNS elemental analyzer
(Waltham, MA, USA). Merck Kieselgel 60F254 plates (Budapest, Hungary) were used for TLC.
The microwave reactions were performed with a CEM Discover SP microwave reactor (Matthwes,
NC, USA).
4.2.1. General Procedure for the Synthesis of Amides (4, 5)
Ethyl 4-hydroxyquinoline-2-carboxylate (3) (1.0 mmol), N1,N1-dimethylethane-1,2-diamine
(2.0 mmol, to achieve 4), or N1,N1-dimethylpropane-1,3-diamine (2.0 mmol, to achieve 5) were
placed in a 50 mL round bottom flask. The mixture was refluxed in 30 mL EtOH for 7–8 h. After
the evaporation of the solvent, the residues were crystallized with Et2O (10 mL). The products were
dissolved in 15 mL of EtOH and HCl/EtOH (22%) was added until reaching pH = 1. Et2O (10 mL) was
added to the solution until precipitation. The crystals were filtered and washed with 2 × 15 mL Et2O
yielding 4 or 5, respectively.
N-(2-(dimethylamino)ethyl)-4-hydroxyquinoline-2-carboxamide hydrochloride (4). Yield: 241 mg (82%); m.p.
150–153 ◦C. 1H-NMR (D2O); 3.03 (6H, s); 3.50 (2H, t, J = 6.0 Hz); 3.88 (2H, t, J = 6.1 Hz); 6.80 (1H, s); 7.54
(1H, t, J = 7.4 Hz); 7.76 (1H, d, J = 8.3 Hz); 7.83 (1H, t, J = 7.9 Hz); 8.12 (1H, d, J = 8.3 Hz); 13C-NMR (D2O);
35.3; 43.2; 53.4; 106.8; 119.4; 124.3; 124.7; 125.8; 134.0; 139.4; 141.7; 163.7; 180.3; ppm. C14H18ClN3O2
(295.76): calcd. C, 56.80; H, 6.09; N, 14.20; found C, 56.73; H, 6.08; N, 14.16.
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N-(3-(dimethylamino)propyl)-4-hydroxyquinoline-2-carboxamide (5). Yield: 238 mg (77%); m.p. 222–226 ◦C.
1H-NMR (D2O); 2.09–2.17 (2H, m); 2.95 (6H, s); 3.28 (2H, t, J = 8.6 Hz); 3.57 (2H, t, J = 6.7 Hz); 6.86
(1H, s); 7.58 (1H, t, J = 7.2 Hz); 7.80 (1H, d, J = 8.0 Hz); 7.86 (1H, t, J = 7.1 Hz); 8.16 (1H, d, J = 8,3 Hz);
13C-NMR (D2O); 24.0; 37.1; 42.9; 55.4; 106.1; 119.5; 124.1; 124.2; 126.3; 134.3; 139.3; 142.5; 162.9; 179.0
ppm. C15H20ClN3O2 (309.79): calcd. C, 58.10; H, 6.46; N, 13.56; found C, 58.14; H, 6.42; N, 13.53.
4-hydroxy-3-(morpholinomethyl)quinoline-2-carboxylic acid (6). Morpholine (174 mg, 2.0 mmol), ethyl
4-hydroxyquinoline-2-carboxylate (3; 217 mg, 1.0 mmol), 22% aqueous formaldehyde (410 mg, 3.0
mmol), and 30 mL of 1,4-dioxane were placed in a 50 mL round bottom flask. The mixture was refluxed
for 6 h. After the evaporation of the solvent, the residue was dissolved in 40 mL water and extracted
with 3 × 30 mL of DCM. The collected organic phases were dried (Na2SO4), the solvent was removed
by evaporation, and the residue was crystallized from 15 mL n-hexane:EtOAc (4:1) to yield 6. Yield:
196 mg (68%); m.p. 253–256 ◦C. 1H-NMR (DMSO); 3.16–3.40 (4H, m); 3.66–3.84 (2H, m); 3.84–4.01 (2H,
m); 4.56 (2H, s); 7.43 (1H, t, J = 7.4 Hz); 7.75 (1H, t, J = 7,9 Hz); 8.04 (1H, d, J = 8.0 Hz); 8.14 (1H, d, J = 7.9
Hz); 10.39 (1H, brs); 12.18 (1H, brs); 13C-NMR (DMSO); 52.0; 52.2; 64.1; 110.7; 120.5; 125.2; 125.5; 125.9;
133.8; 139.9; 143.3; 164.6; 178.2 ppm. C15H16N2O4 (288.30): calcd. C, 62.43; H, 5.55; N, 9.71; found C,
62.38; H, 5.56; N, 9.75.
4.2.2. General Procedure for the Syntheses of Aminoalkylated Amides 7, 8
The 4-hydroxy-3-(morpholinomethyl)quinoline-2-carboxylic acid 6 (1.0 mmol) with
N1,N1-dimethylethane-1,2-diamine (2.0 mmol to achieve 7) or 2-(pyrrolidin-1-yl)ethanamine (2.0
mmol to achieve 8) were dissolved in DMF (20 mL). The reaction was cooled to −10 ◦C while HOBt
(2.0 mmol) was added and the solution was stirred for 10 min. N,N′-diisopropylcarbodiimide (2.0
mmol) was added. After reaching room temperature, the mixture was stirred for additional 7–10
h. After the evaporation of the solvent, the residue was dissolved in 20 mL DCM and was washed
with 2 × 20 mL H2O. The organic phase was dried with Na2SO4 and the solvent was removed under
reduced pressure. The residue was crystallized using Et2O (10 mL) yielding 7 or 8, respectively.
N-(2-(dimethylamino)ethyl)-4-hydroxy-3-(morpholinomethyl)quinoline-2-carboxamide (7). Yield: 161 mg
(45%); m.p. > 350 ◦C. 2.19 (6H, s); 2.41–2.48 (6H, m); 3.45–3.52 (2H, m); 3.53–3.59 (4H, m); 3.60 (2H, s)
7.31 (1H, t, J = 7.3 Hz); 7.64 (1H, t, J = 7.7 Hz); 7.86 (1H, d, J = 8.3 Hz); 8.08 (1H, d, J = 8.1 Hz); 10.63 (1H,
brs); 13C-NMR (DMSO); 38.4; 45.8; 51.0; 52.4; 59.1; 67.0; 113.7; 120.4; 124.4; 124.8; 126.0; 131.0; 132.8;
140.5; 163.9; 177.8; ppm; C19H26N4O3 (358.43): calcd. C, 63.61; H, 7.25; N, 15.62; found C, 63,66; H, 7.26;
N, 15.65.
4-hydroxy-3-(morpholinomethyl)-N-(2-(pyrrolidin-1-yl)ethyl)quinoline-2-carboxamide (8). Yield: 165 mg
(43%); m.p. > 350 ◦C. 1H-NMR (DMSO); 1.63–1.73 (4H, m); 2.46–2.52 (6H, m); 2.64 (2H, t, J = 6.2 Hz);
3.35–3.41 (2H, m); 3.48–3.63 (8H, m); 7.34 (1H, t, J = 7.1 Hz); 7.66 (1H, t, J = 7.2 Hz); 7.88 (1H, d, J = 8.0
Hz); 8.09 (1H, d, J = 8.0 Hz); 10.82 (1H, brs); 11.78 (1H, brs); 13C-NMR (DMSO); 23.6; 50.6; 52.2; 54.1;
55.4; 66.6; 113.4; 119.6; 124.1; 124.3; 125.7; 132.6; 139.7; 144.2; 163.2; 177.6 ppm; C21H28N4O3 (384.47):
calcd. C, 65.54; H, 7.28; N, 14.56; found C, 65.50; H, 7.27; N, 14.55.
4.3. Animals and Housing Conditions
Recordings were made from brain slices taken from 20- to 28-day-old male Wistar rats (N = 62)
supplied by Charles River Laboratories (Wilmington, MA, USA). Animals were kept under constant
environmental conditions (23 Celsius degree; humidity 55 ± 5%; a 12-h/12-h light/dark cycle) and were
housed individually in standard plastic cages, where they had free access to food and water. Every
effort was made to minimize the number of animals used and their suffering. The principles of animal
care (NIH publication No. 85–23) and the protocol for animal care approved both by the Hungarian
Health Committee (1998) and by the European Communities Council Directive (2010/63/EU) were
followed. Ethical license: XX./842/2016. Before the experimental procedures, all the rats were in normal
health and had no neurological deficits.
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4.4. Slice Preparation
Coronal slices (350 µm), prepared from the middle part of their hippocampi with a vibratome
(Leica VT1200S, Wetzlar, Germany), were kept in an ice-cold artificial cerebrospinal solution (ACSF)
composed of (in mM) 130 NaCl, 3.5 KCl, 1 NaH2PO4, 24 NaHCO3, 1 CaCl2, 3 MgSO4, and 10 D-glucose
(all from Sigma, Germany), saturated with 95% O2 + 5% CO2. 3 slices were made from the brain of an
animal. The slices were then transferred to a slice holder chamber, where they were warmed up to
32 ◦C shortly, and then kept 19–20 ◦C until usage to allow the slices to recover in the solution used for
recording (differing only in that it contained 3 mM CaCl2 and 1.5 mM MgSO4). The flow rate in the
Haas-type recording chamber was 1.5–2 mL/min and the experiments were performed at 34 ◦C.
4.5. Electrophysiology
In order to obtain orthodromic stimulation of the Schaffer collateral/commissural pathway,
the stimulating electrode (a bipolar concentric stainless steel electrode developed by Neuronelektrod
Ltd., Hungary) was placed in the stratum radiatum between the CA1 and CA2 regions. The stimulus
intensity was adjusted between 20 and 50 µA (constant current, 0.2-ms pulses delivered at 0.05 Hz) to
evoke the half-maximal response. Field excitatory postsynaptic potentials (fEPSPs) were recorded with
glass micropipettes with a resistance of 1.5–2.5 MΩ filled with ACSF. The recordings were amplified
with a neutralized, high-input-impedance preamplifier and filtered (1 Hz–3 kHz). The fEPSPs were
digitized (AIF-03, Experimetria Ltd., Budapest, Hungary), acquired at a sampling rate of 10 kHz,
saved to a PC, and analyzed off-line with Origin 8.0 software (OriginLab Corporation, Northampton,
MA, USA). The fEPSPs were monitored for 15–20 min until the amplitudes were stable. After having
stabilized the amplitudes, the last 5 min of resting period (before administration of a compound) were
taken as baseline (control, see * in Figure 1A). After baseline recording, KYNA or its analogs were
bath-applied for 30 min, and a wash-out occurred for another 30-min-period. The effect of a compound
was calculated based on the amplitudes obtained during the last 5 min of wash-in period (see # in
Figure 1). The properties of the basal glutamatergic synaptic transmission were also tested by means of
fEPSP recordings; in IO (input-output) graphs the fEPSP amplitudes are expressed against gradually
increasing stimulating currents (0–60 µA, in 5-µA steps) in certain groups (data not shown). Each slice
was subjected to only one measurement [59,60]. 7–10 measurements (N) were carried out in case of
each concentration of each compound, respectively. The actual numbers of measurements (N) are in
the bars of graphs in Figure 2. Altogether, 117 slices were used to test the effects of KYNA and of
its analogs.
5. Statistical Analysis
Field excitatory postsynaptic potentials (fEPSPs) evoked by Schaffer collateral stimulation
were measured from ‘a’ to ‘b’ (see Figure 1A, inset). Origin 8.0 software (OriginLab Corporation,
Northampton, MA, USA) was used for the analyses. Results are expressed as mean ± SEM. One-way
repeated-measures ANOVA with Dunnett post hoc tests was used for assessing the differences between
amplitudes of controls and of KYNA and of its analogs during wash-in.
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